Skip to content

Effect of Darvyadi lauha in the management of Kamala with respect to Hepatocellular jaundice.

Efficacy of Darvyadhi lauha in the management of Hepatocellular jaundice (kamala) and hepatoprotective activity in paracetamol induced hepatotoxicity.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/02/023545
Enrollment
30
Registered
2020-02-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R17- Unspecified jaundice

Interventions

Intervention1: Darvyadhi lauha: 500mg twice daily for a period of 30 days. Control Intervention1: ursodeoxycholic acid: 300mg twice daily for a period of 30 days.

Sponsors

All India institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Diagnosed by elevated bilirubin (Conjugated) in liver function test >1 mg/dl(17 micro mol/L) b) Age :18-50 c) Sex ; either male or female d) Greenish yellow discolouration of skin,sclera ,nails and buccal mucosa(haridra twak ,netra ,nakha,anana) e) Reddish yellow faecal matter and urine(Rakta peeta sakrut mutra) f) Burning sensation (Daha) g) Indigestion(Avipaka) h) Lethargy(Dourbalya) i) Fatigue(Sadana) j) Aruchi(Loss of taste)

Exclusion criteria

Exclusion criteria: 1)Age below 18 years and above 50 years of either sex. 2)Pregnancy 3)Obstructive jaundice 4)Auto immune hepatitis 5)Hepatocellular Carcinoma 6)Liver Transplantation or Any other Condition Interfering with the result of the treatment. 7)Thalassemia major, Sickle cell Disease other haemolytic Jaundices 8)Ca -head of pancreas 9)Gilbertâ??s Syndrome 10)Patients having history of Chronic HTN&DM

Design outcomes

Primary

MeasureTime frame
Reduction in elevated 1)Bilirubin along with L.F.T with changes in Clinical presentation .Timepoint: 0 day, 15th day, 30th day and follow up.

Secondary

MeasureTime frame
Overall improvement in the quality of life.Timepoint: 30th day and follow up.

Countries

India

Contacts

Public ContactDr RamaKant Yadava

All India Institute of Ayurveda

drrky68@gmail.com9412148437

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026